Unmet Needs in cSSTI

The outlook for patients with cSSTI worldwide

Zinforo® offers an efficacious and potent treatment for your patients with cSSTI:1-5

  • Consistently active against common causative pathogens, including MRSA
  • Well-tolerated and efficacious treatment for most patients, including those with comorbidities

Inadequacy of first line treatment

Around 40% of patients with mixed pathogen cSSTIs receive inappropriate initial antimicrobial agents.9,11

Failure of Therapy

Inappropriate initial therapy may result in poor therapy outcome. Initial therapy failure is associated with higher mortality, prolonged hospitalization, and consequent increased cost burden.11

Initial antibiotic treatment modification

*Is defined as the need for a change in initial antibiotic treatment due to insufficient response, adverse reaction, interaction with other drugs, non-suitability of the initial antibiotic based on the results of microbiological tests, or changes to antibiotic therapy or addition of further agents, alone or in combination. The presence of comorbidities is associated with higher rates of initial treatment modification in cSSTI patients6

Day 3 non-response rates

In a retrospective cohort analysis of adult patients, it was observed that non-response rates at Day 3 among cSSTI patients receiving empiric therapy with broad-spectrum antibiotics were high. 9

Longer duration of hospitalisation and antibiotic treatment, and higher costs

In a retrospective cohort analysis of adult patients, it was observed that non-response to initial antibiotic therapy was associated with an overall:10

  • 5.4-day increase in hospital stay
  • 3.7-day increase in the duration of antibiotic administration

Broad-spectrum antibiotics included vancomycin, cefazolin, piperacillin-tazobactam and ampicillin-sulbactam.10
The study does not include data specific to Zinforo® . The study had the inherent limitations associated with a retrospective chart review; because data were initially collected for clinical rather than research purposes. Hence, certain information may have been absent, could have been incomplete or could have been missed by data abstractors.

cSSTI: complicated skin and soft tissue infections; CAP: community acquired pneumonia; MRSA: Methicillin-resistant Staphylococcus aureus

References:
1. Garrison MW, Kawamura NM, Wen MM. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. Expert Rev Anti Infect Ther. 2012;10(10):1087-1103.
2. Casapao AM, Davis SL, Barr VO, et al. Antimicrob Agents Chemother 2014; 58:2541–6.
3. Corey G, Wilcox M, Talbot G, et al. Clin Infect Dis 2010; 51:641–50.
4. Santos PD, Davis A, Jandourek A, et al. J Chemother 2013;25:341–6.
5. Stein GE, Wallace S, Jandourek A, et al. Ceftaroline fosamil for treatment of cSSTI due to Staphylococcus aureus with vancomycin MICs of 1.5 to 2 mg/L: CAPTURE Study Experience.
6. Garau J, Ostermann H, Medina J, et al. Clin Microbiol Infect 2013;19:E377–85.
7. Dryden MS. J Antimicrob Chemother 2010; 65(Suppl. 3):iii35–iii44.
8. Edelsberg J, Berger A, Weber DJ, et al. Infect Control Hosp Epidemiol 2008; 29:160–9.
9. Zilberberg MD, Shorr AF, Micek ST, et al. Infect Control Hosp Epidemiol 2009; 30:1203–10.
10. Amara S, Adamson RT, Lew I. Curr Med Res Opin 2013; 29:869–77.
11. Kaye KS, Petty LA, Shorr AF, et al. Clin Infect Dis. 2019;68(Suppl 3):S193–S199.

PP-ZFO-IND-0279.  09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioner, or a hospital or a laboratory.